Triple Regulator (TIA-39-C20)
Triple-Pathway Metabolic Agonist
Triple Regulator (TIA-39-C20) is a research peptide engineered to engage three complementary metabolic regulatory pathways simultaneously—building on the success of single and dual incretin agonists with even broader metabolic effects.
The Science
What is Triple Regulator?
Triple Regulator peptides combine receptor activity across three complementary pathways—typically GLP-1, GIP, and glucagon (or an amylin-like mechanism)—to maximize metabolic outcomes.
Engaging three pathways may produce additive effects on appetite suppression, glycemic control, energy expenditure, and adipose tissue regulation beyond what dual agonists achieve.
It represents a leading edge of metabolic peptide research, building on the clinical success of tirzepatide and other dual agonists.
Laboratory Observations
Key Observed Effects of Triple Regulator (TIA-39-C20)
Comprehensive Metabolic Support
Targets three regulatory pathways simultaneously.
Appetite Control
Strong satiety effects for caloric control.
Glucose Regulation
Supports healthy glycemic response.
Body Composition
Supports significant body composition change alongside lifestyle.
Mechanism of Action
Mechanism of Action
Triple Regulator activates three metabolic receptor pathways for maximal effect.
Triple Receptor Activation
Engages three complementary pathways for combined metabolic effect.
Appetite Regulation
Strong satiety signaling and reduced caloric intake.
Energy Expenditure
Glucagon-like activity may support increased energy expenditure.
Research-Only Notice
Triple Regulator (TIA-39-C20) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.